Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...

Novo Nordisk is among global pharma leaders in the diabetes and weight loss segments, with indicators of continued demand and sales growth. The firm's profit margin and expected EPS growth beats ...

The drug cost $219 for a month’s supply, a fraction of the list price of $968 for a month’s supply of Ozempic in the U.S. The owners of the home in Boulder say they have no connection to the ...

Novo Nordisk (NYSE: NVO) took a hit on its stock price last week after it received bad news on one of its in-development ...

Novo Nordisk plans to file a label expansion for ... It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or ...

DZ BANK AG analyst Elmar Kraus maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today. The company’s shares closed yesterday at DKK806.92. According to TipRanks, Kraus is a 4 ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Novo Nordisk has been slowly increasing production capacity of its highly coveted weight loss drugs. As a result, thousands of people have began treatment per week. Wegovy has been FDA-approved ...

Oct 21 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a ...

Catalent, a leading contract drug manufacturer, issued an open letter on Monday to reassure customers that a proposed $16.5 billion deal — in which it would be acquired by Novo Nordisk’s ...

Shares of Novo Nordisk (NVO) slipped on Friday following a note from JPMorgan's Richard Vosser. Vosser warned that the pharmaceutical giant's third quarter results could show a slowing in sales of ...